Evidence for Frequent Regression of Cervical Intraepithelial Neoplasia–Grade 2
Top Cited Papers
- 1 January 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 113 (1), 18-25
- https://doi.org/10.1097/aog.0b013e31818f5008
Abstract
OBJECTIVE: To estimate the fraction of cervical intraepithelial neoplasia 2 (CIN 2) that might regress if untreated using data from the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS). METHODS: We compared the cumulative occurrence of CIN 2 (n=397) and CIN 3 or more severe (n=542) diagnosed by the Pathology Quality Control Group in three trial arms—immediate colposcopy, human papillomavirus (HPV) triage, and conservative management—over the 2-year duration of the ALTS trial. A nonparametric test of trend was used to test for differences in the number of CIN 2 cases relative to number of CIN 3 or more severe cases across study arms with an increasing percentage of women referred to colposcopy at baseline. RESULTS: There were no significant differences in the cumulative 2-year cumulative CIN 3 or more severe diagnoses by study arm (10.9%, conservative management; 10.3%, HPV; 10.9%, immediate colposcopy) (Ptrend=.8), but there was a significant increase in CIN 2 diagnoses (5.8%, conservative management; 7.8%, HPV triage; 9.9%, immediate colposcopy) (Ptrend<.001) in the study arms, with increasing number of women referred to colposcopy at baseline. The relative differences in cumulative CIN 2 by study arm among women who tested HPV-16 positive at baseline were less pronounced (Ptrend=.1) than women who tested positive for other high-risk–HPV genotypes (Ptrend=.01). CONCLUSION: There was evidence that approximately 40% of undiagnosed CIN 2 will regress over 2 years, but CIN 2 caused by HPV-16 may be less likely to regress than CIN 2 caused by other high-risk–HPV genotypes. LEVEL OF EVIDENCE: IIKeywords
This publication has 29 references indexed in Scilit:
- Human Papillomavirus Genotype Specificity of Hybrid Capture 2Journal of Clinical Microbiology, 2008
- Heterogeneity in CIN3 diagnosisThe Lancet Oncology, 2008
- Risk assessment to guide the prevention of cervical cancerAmerican Journal of Obstetrics and Gynecology, 2007
- 2006 consensus guidelines for the management of women with abnormal cervical cancer screening testsAmerican Journal of Obstetrics and Gynecology, 2007
- Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening testsInternational Journal of Cancer, 2006
- Socioeconomic status and the risk of cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA‐positive women with equivocal or mildly abnormal cytologyCancer, 2005
- Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significanceAmerican Journal of Obstetrics and Gynecology, 2003
- A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretationsAmerican Journal of Obstetrics and Gynecology, 2003
- Human Papillomavirus Testing for Triage of Women With Cytologic Evidence of Low-Grade Squamous Intraepithelial Lesions: Baseline Data From a Randomized TrialJNCI Journal of the National Cancer Institute, 2000
- ASCUS-LSIL Triage StudyActa Cytologica, 2000